<p>/PRNewswire/ -- 药明康德（NASDAQ: ACXP）（&#34;我们&#34;或&#34;药明&#34;或&#34;公司&#34;）是一家处于后期阶段的生物制药公司，专注于开发针对难治性细菌感染的新型抗生素，今天宣布完成其之前宣布的注册直接发行 246,3058 股普通股，购买价格为每股 1.015 美元，按照纳斯达克规则以市场价格定价。此外，在同时进行的私募中，公司发行了未注册的认股权证，最多可购买 246,3058 股普通股。认股权证的行使价格为每股 0.90 美元，发行时可行使，并在发行日期后五年到期。</p>
<p>H.C. Wainwright &amp; Co. 担任此次发行的独家配售代理。</p>
<p>此次发行公司获得的总毛收益约为 250 万美元，未扣除公司需支付的配售代理费用和其他发行费用。公司目前打算将此次发行的净收益用于营运资金和其他一般企业用途。</p>
<p>普通股（但不包括在私募中发行的认股权证或与这些认股权证相关的普通股）是根据 2022 年 7 月 1 日向证券交易委员会（&#34;SEC&#34;）提交的&#34;货架&#34;注册声明（文件编号 333-265956）进行发行的，该注册声明于 2022 年 7 月 11 日生效。普通股的注册直接发行仅通过招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与注册直接发行的普通股相关的招股说明书补充及随附招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。与注册直接发行相关的招股说明书补充及随附招股说明书的电子版也可通过联系 H.C. Wainwright &amp; Co., LLC，地址为 430 Park Avenue, 3rd Floor, New York, NY 10022，电话 (212) 856-5711 或电子邮件 placements@hcwco.com 获取。</p>
<p>上述认股权证是在 1933 年证券法（&#34;证券法&#34;）第 4(a)(2) 条及其下的 D 条款的规定下，在同时进行的私募中发行的，并且与认股权证相关的普通股未根据证券法或适用的州证券法进行注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则认股权证和相关的普通股不得在美国进行发行或销售。</p>
<p>本新闻稿不构成出售或招揽购买本文所述任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证之前，此类要约、招揽或销售是非法的。</p>
<p><strong>关于药明康德</strong></p>
<p>药明康德是一家处于后期阶段的生物制药公司，专注于开发针对难治性细菌感染的新型小分子抗生素。公司的方法是开发具有革兰氏阳性选择性谱（GPSS®）的抗生素候选药物，阻断革兰氏阳性特异性细菌酶 DNA 聚合酶 IIIC（pol IIIC）的活性位点，抑制 DNA 复制并导致革兰氏阳性细菌细胞死亡。其研发管线包括针对革兰氏阳性细菌的抗生素产品候选药物，包括艰难梭菌、耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）、耐药性肺炎链球菌（DRSP）和炭疽杆菌（炭疽；生物恐怖主义 A 类威胁级病原体）。药明康德的主要产品候选药物 ibezapolstat 用于治疗艰难梭菌感染，已准备进入第三阶段，计划在今年开始国际临床试验。公司的临床前管线包括开发用于治疗急性细菌皮肤及皮肤结构感染（ABSSSI）的口服产品候选药物，并计划与之并行开发用于治疗吸入性炭疽的开发项目。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中关于我们未来期望、计划和前景的任何声明，包括关于我们战略、未来运营、前景、计划和目标的声明，以及包含 “相信”、“预期”、“计划”、“期望” 和类似表达的其他声明，构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明包括关于本次发行收益使用的声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：市场及其他条件，ibezapolstat 是否会受益于 QIDP 认证；ibezapolstat 是否会按时推进临床试验过程；ibezapolstat 的临床试验结果是否足以支持提交市场批准申请，如果是，ibezapolstat 是否会获得 FDA 或其他寻求批准的外国监管机构的批准；如果 ibezapolstat 获得批准，是否能够成功分销和营销；以及在公司向证券交易委员会提交的 2023 年 12 月 31 日结束的年度报告的 10-K 表格中以及公司随后向证券交易委员会提交的文件中描述的其他风险和不确定性。这些前瞻性声明仅在本新闻稿日期有效，Acurx 不承担更新这些前瞻性声明以反映该声明日期之后事件或情况的意图或义务，除非法律要求。</p>
<p><strong>投资者联系：</strong></p>
<p>Acurx Pharmaceuticals, Inc.</p>
<p>大卫·P·卢奇，董事长兼首席执行官</p>
<p>电话：917-533-1469</p>
<p>电子邮件：davidluci@acurxpharma.com</p>
<p>来源：Acurx Pharmaceuticals, Inc.</p>

ACXP

<p>Acurx Pharmaceuticals, Inc. 已完成一项注册直接发行，发行了 2,463,058 股普通股，价格为每股 1.015 美元，筹集了约 250 万美元。该公司还发行了相同数量的未注册认股权证，行使价格为 0.90 美元。筹集的资金将用于营运资金和一般企业用途。H.C. Wainwright & Co. 担任独家配售代理。此次发行是在向美国证券交易委员会（SEC）提交的货架注册声明下进行的</p>

<p>, /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (&#34;we&#34; or &#34;Acurx&#34; or the &#34;Company&#34;), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 2,463,058 shares of its common stock at a purchase price of $1.015 per share priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,463,058 shares of common stock. The warrants have an exercise price of $0.90 per share, are exercisable upon issuance and expire five years following the date of issuance.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 药明康德（NASDAQ: ACXP）（&#34;我们&#34;或&#34;药明&#34;或&#34;公司&#34;）是一家处于后期阶段的生物制药公司，专注于开发针对难治性细菌感染的新型抗生素，今天宣布完成其之前宣布的注册直接发行 246,3058 股普通股，购买价格为每股 1.015 美元，按照纳斯达克规则以市场价格定价。此外，在同时进行的私募中，公司发行了未注册的认股权证，最多可购买 246,3058 股普通股。认股权证的行使价格为每股 0.90 美元，发行时可行使，并在发行日期后五年到期。</p>
</div><p>H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</p>
<div class="lb-trans"><p>H.C. Wainwright &amp; Co. 担任此次发行的独家配售代理。</p>
</div><p>The aggregate gross proceeds to the Company from the offering were approximately $2.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>此次发行公司获得的总毛收益约为 250 万美元，未扣除公司需支付的配售代理费用和其他发行费用。公司目前打算将此次发行的净收益用于营运资金和其他一般企业用途。</p>
</div><p>The shares of common stock (but not the warrants issued in the private placement or the shares of common stock underlying such warrants) were offered by the Company pursuant to a &#34;shelf&#34; registration statement on Form S-3 (File No. 333-265956) filed with the Securities and Exchange Commission (&#34;SEC&#34;) on July 1, 2022 and became effective on July 11, 2022. The registered direct offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the shares of common stock offered in the registered direct offering were filed with the SEC and are available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.</p>
<div class="lb-trans"><p>普通股（但不包括在私募中发行的认股权证或与这些认股权证相关的普通股）是根据 2022 年 7 月 1 日向证券交易委员会（&#34;SEC&#34;）提交的&#34;货架&#34;注册声明（文件编号 333-265956）进行发行的，该注册声明于 2022 年 7 月 11 日生效。普通股的注册直接发行仅通过招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与注册直接发行的普通股相关的招股说明书补充及随附招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。与注册直接发行相关的招股说明书补充及随附招股说明书的电子版也可通过联系 H.C. Wainwright &amp; Co., LLC，地址为 430 Park Avenue, 3rd Floor, New York, NY 10022，电话 (212) 856-5711 或电子邮件 placements@hcwco.com 获取。</p>
</div><p>The warrants described above were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</p>
<div class="lb-trans"><p>上述认股权证是在 1933 年证券法（&#34;证券法&#34;）第 4(a)(2) 条及其下的 D 条款的规定下，在同时进行的私募中发行的，并且与认股权证相关的普通股未根据证券法或适用的州证券法进行注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则认股权证和相关的普通股不得在美国进行发行或销售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买本文所述任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证之前，此类要约、招揽或销售是非法的。</p>
</div><p><strong>About Acurx Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于药明康德</strong></p>
</div><p>Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&amp;D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials this year. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.</p>
<div class="lb-trans"><p>药明康德是一家处于后期阶段的生物制药公司，专注于开发针对难治性细菌感染的新型小分子抗生素。公司的方法是开发具有革兰氏阳性选择性谱（GPSS®）的抗生素候选药物，阻断革兰氏阳性特异性细菌酶 DNA 聚合酶 IIIC（pol IIIC）的活性位点，抑制 DNA 复制并导致革兰氏阳性细菌细胞死亡。其研发管线包括针对革兰氏阳性细菌的抗生素产品候选药物，包括艰难梭菌、耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）、耐药性肺炎链球菌（DRSP）和炭疽杆菌（炭疽；生物恐怖主义 A 类威胁级病原体）。药明康德的主要产品候选药物 ibezapolstat 用于治疗艰难梭菌感染，已准备进入第三阶段，计划在今年开始国际临床试验。公司的临床前管线包括开发用于治疗急性细菌皮肤及皮肤结构感染（ABSSSI）的口服产品候选药物，并计划与之并行开发用于治疗吸入性炭疽的开发项目。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words &#34;believes,&#34; &#34;anticipates,&#34; &#34;plans,&#34; &#34;expects,&#34; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the use of proceeds from the offering. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market and other conditions, whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.</p>
<div class="lb-trans"><p>本新闻稿中关于我们未来期望、计划和前景的任何声明，包括关于我们战略、未来运营、前景、计划和目标的声明，以及包含 “相信”、“预期”、“计划”、“期望” 和类似表达的其他声明，构成 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明包括关于本次发行收益使用的声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：市场及其他条件，ibezapolstat 是否会受益于 QIDP 认证；ibezapolstat 是否会按时推进临床试验过程；ibezapolstat 的临床试验结果是否足以支持提交市场批准申请，如果是，ibezapolstat 是否会获得 FDA 或其他寻求批准的外国监管机构的批准；如果 ibezapolstat 获得批准，是否能够成功分销和营销；以及在公司向证券交易委员会提交的 2023 年 12 月 31 日结束的年度报告的 10-K 表格中以及公司随后向证券交易委员会提交的文件中描述的其他风险和不确定性。这些前瞻性声明仅在本新闻稿日期有效，Acurx 不承担更新这些前瞻性声明以反映该声明日期之后事件或情况的意图或义务，除非法律要求。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Acurx Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Acurx Pharmaceuticals, Inc.</p>
</div><p>David P. Luci, President &amp; Chief Executive Officer</p>
<div class="lb-trans"><p>大卫·P·卢奇，董事长兼首席执行官</p>
</div><p>Tel: 917-533-1469</p>
<div class="lb-trans"><p>电话：917-533-1469</p>
</div><p>Email: davidluci@acurxpharma.com</p>
<div class="lb-trans"><p>电子邮件：davidluci@acurxpharma.com</p>
</div><p>SOURCE Acurx Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Acurx Pharmaceuticals, Inc.</p>
</div>

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | ACXP Stock News

StockTitan

Acurx Pharmaceuticals, Inc. 宣布根据纳斯达克规则以市场价格完成 250 万美元的注册直接发行 | ACXP 股票新闻